Emory University;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
FREEMAN, Gordon J.,AHMED, Rafi,JONES, Timothy D.,CARR, Francis J.,GREGSON, James P.
申请号：
AU2016222431
公开号：
AU2016222431A1
申请日:
2016.09.01
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
#$%^&*AU2016222431A120160922.pdf#####Abstract The present invention is based, in part, on the identification of novel human anti-PD1, PD-Li, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-Li, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-Li, and PD-L2 antibodies described herein. 8131965_1 (GHMatters) P86720.AU.3
